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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

A STATE’S EFFORT TO ENHANCE HEALTH CARE:
EMPOWERING PHARMACISTS WITH PRESCRIBING AUTHORITY

ABSTRACT
High rates of unintended pregnancies and costs associated with them have
been a concern for the health care system in the U.S. The State of Oregon took
a unique approach to reduce unintended pregnancy rates within its borders.
Oregon enacted a statute that authorized pharmacists to prescribe hormonal
contraceptives, which expanded the scope of practice of pharmacists. This
Article explores whether states, instead of the Food and Drug Administration
(FDA), should regulate the scope of practice of health care professionals. This
Article further explores the impact of Oregon’s law on access to hormonal
contraceptives, safety of women’s health, and costs for patients or the health
care system. This Article concludes that Oregon, and states in general, is in a
better position than the FDA to regulate the practice of health care
professionals. Also, Oregon’s law will increase access to hormonal
contraceptives without jeopardizing the safety of women’s health and will not
increase costs for patients or for the health care system.
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I. INTRODUCTION
Contraception is named as one of the greatest public health achievements of
the twentieth century by the Centers for Disease Control and Prevention (CDC). 1
Still, however, the rates of unintended pregnancy are higher in the U.S. than in
most other developed countries. 2 Reducing these rates has been identified as a
national priority by the Department of Health and Human Services (HHS). 3
On January 1, 2016, the State of Oregon took an unprecedented step to
reduce unintended pregnancy rates within its borders. The state enacted a statute
that authorized pharmacists to prescribe oral and transdermal contraceptives to
women aged eighteen years or older. 4 This law also allowed pharmacists to
prescribe to women younger than eighteen years of age who have a previous
prescription from a primary care provider. 5
Oregon’s new law has raised concerns in the legal and medical communities.
This law is giving pharmacists an authority to prescribe, a power that
pharmacists have never exercised before in providing health care. The legal
community’s concern is whether states, instead of the Food and Drug
Administration (FDA), have and should be allowed to have the power to expand
and regulate the practice of health care professionals. 6 Through this law,
pharmacists will be prescribing to millions of women and exercising

1. See Ten Great Public Health Achievements – United States, 1900–1999, 48 CTRS. FOR
DISEASE CONTROL & PREVENTION MORBIDITY & MORTALITY WKLY. REP. 241, 241 (1999),
https://www.cdc.gov/mmwr/preview/mmwrhtml/00056796.htm; see also ADAM SONFIELD ET AL.,
GUTTMACHER INST., THE SOCIAL AND ECONOMIC BENEFITS OF WOMEN’S ABILITY TO
DETERMINE WHETHER AND WHEN TO HAVE CHILDREN 3 (2013), https://www.guttmacher.org/
sites/default/files/report_pdf/social-economic-benefits.pdf (describing benefits of contraception
and how it has improved family planning for women).
2. See Gilda Sedgh et al., Intended and Unintended Pregnancies Worldwide in 2012 and
Recent Trends, 45 STUD. FAM. PLAN. 301, 306 (2014) (stating that the rates of unintended
pregnancy have remained significantly higher in the U.S. than in other developed countries for
many years); see also Wm. Robert Johnston, Abortion Rates by Country (Countries Listed by
Name), JOHNSTON’S ARCHIVE (Feb. 25, 2017), http://www.johnstonsarchive.net/policy/abortion/
wrjp336abrate2.html; GUTTMACHER INST., FACT SHEET: UNINTENDED PREGNANCY IN THE
UNITED STATES 1 (2019), https://www.guttmacher.org/fact-sheet/unintended-pregnancy-unitedstates.
3. U.S. Dep’t of Health and Hum. Servs., Healthy People 2020 Summary of Objectives:
Family Planning, OFF. DISEASE PREVENTION & HEALTH PROMOTION (Mar. 18, 2018),
http://www.healthypeople.gov/2020/topics-objectives/topic/family-planning/objectives/; see also
Lawrence B. Finer & Mia R. Zolna, Unintended Pregnancy in the United States: Incidence and
Disparities, 2006, 84 CONTRACEPTION 478, 478 (2011).
4. OR. REV. STAT. § 689.689(1)(a) (2017) (emphasis added).
5. OR. REV. STAT. § 689.689(1)(b) (2017).
6. See generally Patricia J. Zettler, Pharmaceutical Federalism, 92 IND. L.J. 845, 892 (2017);
Jesse C. Vivian, Pharmacists Prescribing Birth Control, US PHARMACIST 48, 50 (2016) (stating
that Oregon is the first state to enact such law and other states are following Oregon, where legality
of such laws is uncertain).
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independent treatment judgment that will directly affect women’s health and use
of hormonal contraceptives in the state. The medical community’s concern is
that allowing pharmacists to prescribe might not increase access to hormonal
contraceptives, because women may not be willing to receive prescriptions from
pharmacists as pharmacists are not used to making independent treatment
decisions. 7 The medical community is also concerned that this law might
jeopardize safety, because pharmacists are not accustomed to evaluating
patients’ conditions and treating them with prescription-only drugs. 8 This raises
an additional concern that costs for patients and for the health care system might
increase.
However, Oregon’s model offers strong solutions that likely resolve all
concerns of the legal and medical communities. This article describes these
solutions by evaluating legal, scientific, and scholarly literature via an
interdisciplinary approach. Regarding the legal community’s concern, this
Article proposes that states have the authority to regulate the practice of health
care professionals, because this power has been granted to them by the
Fourteenth Amendment and has been acknowledged by the Supreme Court of
the United States. Moreover, this Article advocates three major reasons that
demonstrate Oregon, and states in general, is in a better position than the FDA
to regulate the practice of health care professionals. First, Oregon will be able to
respond to local access needs of its citizens more effectively and quickly than
the FDA. Second, Oregon can enact laws that will allow health care
professionals to address clinical needs of individual patients. Third, Oregon can
enforce regulations and supervise the practice of health care professionals more
closely and effectively than the FDA.
Regarding the medical community’s concerns, this Article proposes that
Oregon’s model will increase access to hormonal contraceptives. Clinical
studies have shown that allowing pharmacists to prescribe hormonal
contraceptives actually increases access, because women are willing and feel
safe to receive hormonal contraceptive prescriptions from pharmacists. Also,
this was evident by an increase in sales of hormonal contraceptives in those
studies. Oregon’s model will not jeopardize safety of women’s health; rather it
will improve their health. The clinical studies have also proved that pharmacists
can prescribe medications more safely, in fact, than physicians. Oregon’s model
7. See FDA Proposal to Allow Pharmacists to Prescribe Some Drugs Sparks Swift Rebuke
from AAFP, AM. ACAD. OF FAM. PHYSICIANS (May 2, 2012), https://www.aafp.org/news/govern
ment-medicine/20120502pharmprescribing.html.
8. See Sarah Breitenbach, States Start to Let Pharmacists Prescribe Birth Control Pills, PEW
CHARITABLE TR. (Feb. 18, 2016), http://www.pewtrusts.org/en/research-and-analysis/blogs/state
line/2016/02/18/states-start-to-let-pharmacists-prescribe-birth-control-pills
(stating
that
pharmacists are unable to safely examine women and recommend hormonal contraceptives); see
also Daisy Contreras, Pharmacist’s Order: Birth Control Without the Doctor, NPR: ILL. (Aug. 9,
2018), http://www.nprillinois.org/post/pharmacists-order-birth-control-without-doctor#stream/0.
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will not increase costs for patients or for the health care system. Finally, the
studies have shown that increasing access to hormonal contraceptives reduces
unintended pregnancy and abortion rates, which decreases overall health care
cost. Also, with Oregon’s model, the cost for patients will not increase, because
prescriptions from pharmacists will be covered by insurance and patients will
pay nothing or reduced costs for their prescriptions.
Part II of this Article is divided into two sections. Section A will discuss the
FDA’s authority in regulating public health. This section will describe the
FDA’s role and involvement specifically in the drug approval process. Section
B will discuss congruent authority of states in regulating public health. This
section will describe states’ roles in supervising the practice of health care
professionals and also draw a distinction from the FDA’s authority.
Part III of this Article also is divided into two sections. Section A will
discuss the history and development of hormonal contraceptives. This section
will describe the characteristics that led to their prescription-only status. Section
B will discuss the authority of the FDA to switch a drug from prescription-only
to non-prescription status and the scientific data it analyzes in making a switch.
This section will describe the switch of one hormonal contraceptive drug,
levonorgestrel (Plan B), to non-prescription status and how that impacts the
public’s access to the drug.
Part IV of this Article is divided into four sections. Section A will analyze
Oregon’s new law and its scope pursuant to a state’s power recognized by the
federal courts. This section will examine whether Oregon, compared to the FDA,
is in a better position to regulate the practice of health care professionals. Section
B will discuss the legislative intent behind Oregon’s new law and whether there
is a need to increase access to hormonal contraceptives. This section will
investigate whether women are willing to receive hormonal contraceptive
prescriptions from pharmacists and whether allowing pharmacists to prescribe
hormonal contraceptives can actually increase access. Section C will analyze the
impact of Oregon’s new law on safety of women’s health. This section will
examine whether women feel safe in receiving hormonal contraceptive
prescriptions from pharmacists and whether pharmacists can prescribe them
safely. Section D will analyze the impact of Oregon’s new law on costs for
patients and for the health care system. This section will also discuss whether
Oregon has taken any measures to reduce the financial burden on patients.
Part V of this Article will provide an overview of solutions to the legal and
medical communities’ concerns addressed in Part IV. This section will also
summarize the authority of states and the FDA in regulating public health and
will assess whether Oregon is in a better position to regulate the practice of
health care professionals. This section further will conclude on impact of
Oregon’s new law on access, safety, and cost of hormonal contraceptive use in
the state.
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II. BACKGROUND REGULATION
This Part will discuss the congruent power of the FDA and states in
regulating public health. This Part also will draw a distinction between these
powers and describe how regulating drugs is reserved to the FDA and regulating
the practice of health care professionals is reserved to states.
A.

The Food and Drug Administration’s Power to Regulate Drugs

The FDA is a federal regulatory agency that protects the public by regulating
the safety, efficacy, and quality of drugs marketed in the country. 9 The FDA also
assures that all necessary information is available to the public for safe use of
drugs. 10 The FDA is well-known for its “gatekeeping” authority for entry of new
drugs in the market. 11 As per 21 U.S.C. § 355(a), “[n]o person shall introduce or
deliver for introduction into interstate commerce any new drug, unless an
approval of an application [by the FDA].” 12 Thus the FDA is a gatekeeper to
new drugs, because they cannot be sold or marketed in the U.S. without its
approval.
In addition to the authority to supervise entry of new drugs, the FDA also
has the authority to further restrict their access. The Food, Drug, and Cosmetic
Act authorizes the FDA to assign ‘prescription-only’ status to drugs upon
finding that “[the drug’s] toxicity or other potentiality for harmful effect, or the
method of its use, or the collateral measures necessary to its use, is not safe for
use except under the supervision of a practitioner licensed by law to administer
[it].” 13 Thus, the FDA can restrict access of certain drugs, making them available
only via prescription from a licensed practitioner.
Moreover, the FDA’s authority covers the “entire lifecycle of a drug,” from
the early stages of research to its approval. To approve a drug for sale in the
U.S., the FDA must determine that the drug is safe and effective for its proposed
indication by the manufacturer. 14 The safety and effectiveness must be shown
via “substantial evidence,” which includes data from “adequate and wellcontrolled” clinical trials. 15 After a manufacturer applies for approval of a drug,
the FDA and the manufacturer are constantly in communication throughout the
approval process of the drug. 16 The FDA also conducts advisory committee
meetings, where drug experts can raise concerns regarding the drug. 17 The FDA
9. What We Do, FDA (Mar. 28, 2018), https://www.fda.gov/about-fda/what-we-do.
10. Id.
11. Zettler, supra note 6, at 857.
12. 21 U.S.C. § 355(a) (2012).
13. Id. § 353(b)(1).
14. Id. § 355(d).
15. Id.
16. See 21 C.F.R. § 314.102(a) (2016) (stating that the “FDA shall communicate with
applicants about scientific, medical, and procedural issues that arise during the review process”).
17. Id. § 314.103(c)(3).
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also assures that the proposed labeling is not false or misleading and “good
manufacturing practice” was used during the development of the drug. 18 When
the FDA decides to approve a new drug, it provides the public with
comprehensive scientific data that supports its approval decision. 19 Thus, the
FDA’s collaborative and extremely comprehensive new drug approval process
covers the entire lifecycle of a drug. 20
Despite the intense effort involved in the FDA approval process, the FDA’s
approval is limited as it does not determine that the drug is “generally” safe and
effective. Instead, the FDA determines that a drug is safe and effective only for
a particular use proposed by the manufacturer, that is, to treat a specific
condition at a particular dose in a certain patient population. 21 However, once
the FDA approves a drug, physicians may prescribe the drug for any other
conditions, including unapproved uses, known as “off-label” uses. 22
Thus, the FDA is not only a gatekeeper to new drugs, but it also has the
authority to further restrict access to them. The laws also allow the FDA to be
actively involved in every step of the drug development and approval process.
This expansive power of the FDA enables it to regulate public health via its
supervision at every stage of a drug’s lifecycle.
B.

The States’ Power to Regulate the Practice of Health Care Professionals

It is a well-established principle, arising from the Supreme Court’s decision,
that states have the power to regulate the practice of health care professionals.
In Graves v. State of Minnesota, the Supreme Court stated that “a state may,
consistently with the Fourteenth Amendment, prescribe that only persons
possessing the reasonably necessary qualifications of learning and skill shall
practise [sic] medicine[.]” 23 This recognition is based on the rationale that for
the general welfare of its citizens, a state, in its judgment, is allowed to enact
laws to regulate the practice of health care professionals to protect its citizens
from harm caused by the incompetent and unethical practice of health care. 24
In addition, federal courts have distinguished between the congruent
authority of states and the FDA regarding protecting the public. In United States
v. Evers, the Fifth Circuit clarified that the FDA was not intended and does not
have the authority to regulate the practice of health care professionals. 25 The
circuit court further stated that the FDA was only intended to “control the
18. Id. § 314.125(b)(6), (13).
19. Id. § 314.430(e).
20. Zettler, supra note 6, at 858.
21. See Rebecca Dresser & Joel Frader, Off-Label Prescribing: A Call for Heightened
Professional and Government Oversight, 37 J. L. MED. & ETHICS 476, 477 (2009).
22. Id. at 476, 477.
23. Graves v. State of Minn., 272 U.S. 425, 427 (1926).
24. Id.
25. United States v. Evers, 643 F.2d 1043, 1048 (5th Cir. 1981).
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availability of drugs” that practitioners could prescribe. 26 Similarly, in United
States v. Regenerative Sciences, LLC, the FDA stated that Congress did not
intend for the FDA to regulate the practice of health care professionals. 27
Moreover, the court, supporting the FDA’s view, also noted that Congress left
the practice of health care professionals for states to regulate. 28 Thus, the federal
courts have distinguished between regulation of products and regulation of
practice.
This distinction between practice and products serves as the dividing line
between state and federal regulation. In October 2013, the FDA approved
Zohydro ER, a new, high-dose opioid medication. 29 The State of Massachusetts,
in an attempt to address opioid addiction problems, prohibited “prescribing and
dispensing” of Zohydro ER by practitioners within its borders, because this new
medication lacked abuse-resistant formulation. 30 Here, the state’s regulation
contradicted the FDA’s approval of Zohydro ER to be widely available for
practitioners throughout the country. The court considered whether Congress
intended FDA oversight to preempt state regulation and whether Massachusetts
intended to regulate drugs. 31 The court reasoned that FDA’s approval of countrywide availability of Zohydro ER preempted state regulations. 32 The court further
reasoned that Massachusetts intended to regulate Zohydro ER even though the
prohibition in the statute technically applied only to practitioners. 33 The court
concluded that the state cannot indirectly regulate medical products via medical
practice regulations. 34 Hence, the federal courts have acknowledged medical
practice regulation pursuant to states’ police powers and medical product
regulations pursuant to the FDA’s power.
However, there are some examples where state regulations have extended
their reach and entered into the federal drug regulation arena. Over thirty states
have passed “right-to-try” laws that permit terminally-ill patients access to drugs
that are unapproved by the FDA. 35 At least thirty-four states have enacted laws
that allow use of marijuana for medical purposes, regardless of whether the FDA
has approved marijuana for medical purposes or whether such laws are

26. Id.
27. United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1319–20 (D.C. Cir. 2014).
28. Id. at 1319.
29. Zogenix, Inc. v. Patrick, No. 14-11689-RWZ, 2014 WL 1454696, at *1 (D. Mass. Apr.
15, 2014).
30. Id.
31. Id. at *2.
32. Id.
33. Id.
34. Zogenix, 2014 WL 1454696, at *2.
35. Melissa Healy, Dying Patients Want Easier Access to Experimental Drugs. Here’s Why
Experts Say That’s Bad Medicine, L.A. TIMES (Mar. 14, 2017), http://www.latimes.com/science/sci
encenow/la-sci-right-to-try-medicines-20170314-story.html.
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consistent with the federal Controlled Substances Act. 36 The constitutionality of
these state regulations still remains uncertain.
Hence, states have the authority to regulate the practice of health care
professionals. The federal courts have distinguished and acknowledged medical
practice regulation as a power reserved to states and medical product regulation
as a power reserved to the FDA.
III. HORMONAL CONTRACEPTIVES
This part will describe why hormonal contraceptives are assigned
prescription-only status. This part will also address why the FDA decided to
assign non-prescription status to Plan B and how that affects the public’s access
to the drug.
A.

History and Nature of Hormonal Contraceptives

A hormonal contraceptive, also known as birth control drug, is any pill,
injection, or device that uses hormones to prevent pregnancy. 37 In 1960, the
FDA approved the first oral contraceptive: a pill containing mestranol and
norethynodrel. 38 This medication became quite popular upon its approval, but
its high-dose formulation caused blood-clotting problems (like venous
thromboembolism and arterial vascular events) that led to the increase in
mortality risk among its users. 39 With significant research and development in
hormone therapy, low-dose, low-risk formulations with estrogen and progestin
were developed. 40 In the 1970s, a progestin-only pill containing norethindrone,
also known as the mini pill, became widely available in the country. 41 The mini
pill was less effective than previous formulations, because it only contained
progestin; yet it was considered comparatively safe. 42 In the 1990s, hormone
combination formulations containing estrogen and progestin were developed
36. State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (March 5, 2019),
http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
37. Hormonal Birth Control, LEXICOMP ONLINE (Oct. 11, 2017), http://www.crlonline.com/
lco/action/doc/retrieve/docid/disandproc/4147842 (source on file with author).
38. Frank B. Colton, Steroids and “The Pill”: Early Steroid Research at Searle, 57 STEROIDS
624, 628 (1992).
39. Risk of Thromboembolic Disease in Women Taking Oral Contraceptives: A Preliminary
Communication to the Medical Research Council by A Subcommittee, 2 BRIT. MED. J. 355, 359
(1967).
40. W. H. W. Inman et al., Thromboembolic Disease and the Steroidal Content of Oral
Contraceptives: A Report to the Committee on Safety of Drugs, 2 BRIT. MED. J. 203, 204, 207
(1970) (describing how combined regimens of estrogen and progestogen were developed).
41. Diana B. Petitti & Stephen Sidney, Four Decades of Research on Hormonal
Contraception, 9 PERMANENTE J. 29, 29, 31 (2005); Types of Birth Control Pills, EMEDEXPERT,
https://www.emedexpert.com/classes/birth-control-types.shtml (last visited Apr. 13, 2019).
42. See James Trussell, Contraceptive Failure in the United States, 83 CONTRACEPTION 397,
399, 401 (2011).
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(containing one-third to one-fifth of the amount of estrogen and various amounts
of progestin). 43
Most hormonal contraceptives now contain both progestin and estrogen.44
Progestin suppresses ovulation by prohibiting the surge of follicle-stimulating
hormone and luteinizing hormone, thickening cervical mucus, and keeping the
endometrium lining thin. 45 Estrogen also suppresses ovulation in the ovaries and
prevents breakdown of the endometrium lining in the uterus. 46 Thus, progestin
and estrogen together in hormonal contraceptives work to make the uterus
inhospitable for implantation of a fertilized egg, and thereby prevent pregnancy.
Hormonal contraceptives come in various formulations: pills, patches,
vaginal rings, injections, implants, and intrauterine devices (IUDs). 47 Selection
of the appropriate formulation for a particular patient requires medical judgment,
as each of these formulations has different dosing schedules and mechanisms of
function. With oral pills, practitioners recommend women take a pill every day;
women who prefer not to get a period are recommended to skip the hormonefree pills in the pack and take a hormone pill every day instead. 48 With skin
patches, practitioners recommend women wear the patch on the upper arm,
shoulder, back, or hip for three weeks (a new patch each week), and then leave
the patch off during week four when they have their period. 49 With vaginal rings,
practitioners recommend women put the hormonal ring in the vagina for three
weeks at a time and remove the ring during week four. 50 With injections,
practitioners give a hormone shot to women in the arm or buttocks every four
months. 51 With implants, practitioners inject a tiny rod in the arm that releases
hormones, and the rod can stay in the arm for up to three years. 52 With IUDs,
practitioners place a device inside the uterus that releases hormones. 53 Thus,
selection and use of hormonal contraceptives is done under direct supervision
and direction of health care practitioners.
Hormonal contraceptives interact with many common medications, and
practitioners will check such interactions before prescribing particular
contraceptives. Hormonal contraceptives interact with rifamycin-class
antibiotics like rifampin, rifabutin, rifapentine; anti-seizure medications like
43. Petitti & Sidney, supra note 41, at 32.
44. Hormonal Birth Control, supra note 37.
45. Kathryn A. Martin & Robert L. Barbieri, Overview of the Use of Estrogen-Progestin
Contraceptives, UPTODATE (Sept. 25, 2018), https://www.uptodate.com/contents/overview-ofthe-use-of-combined-estrogen-progestin-oral-contraceptives (source on file with author).
46. Id.
47. Hormonal Birth Control, supra note 37.
48. See Martin & Barbieri, supra note 45.
49. Hormonal Birth Control, supra note 37.
50. Id.
51. Id.
52. Id.
53. Id.
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barbiturates, carbamazepine, phenytoin; antiviral medications containing
ritonavir; and herbal remedies such as St. John’s wort. 54 These interactions can
reduce the efficacy of either the hormonal contraceptives or of the additional
medication. 55 The interactions are significant enough to warrant intervention by
a practitioner of either a different approach to contraception or a different
medication for the underlying condition. 56 Thus, interactions of hormonal
contraceptives with numerous drugs require them to be prescribed under the
supervision of an experienced health care practitioner.
Moreover, hormonal contraceptives require careful assessment of medical
history of a patient. Before prescribing, practitioners generally measure the
patient’s blood pressure and also calculate the patient’s body mass index,
because obese patients are at greater risk for blood-clotting side-effects (venous
thromboembolism) of hormonal contraceptives. 57 Practitioners also assess for
symptoms of blood-clotting diseases like chest pain, shortness of breath, and
cough. 58 They also look for new or worsened migraines or headaches associated
with neurologic signs like confusion, dizziness, and visual disturbances, which
prohibit use of hormonal contraceptives and warrant evaluation of the
underlying condition. 59 While breast exams, Pap smears, and screening for
sexually transmitted diseases are important, many professional medical groups,
including the American College of Obstetricians and Gynecologists and the
World Health Organization, suggest that these procedures are unnecessary
before the first prescription. 60 Hence, prescription of hormonal contraceptives
requires appropriate evaluation of medical history and health of a patient by a
practitioner.
Therefore, research in hormonal contraceptives has been moving toward
development of low-risk, low-dose formulations. Hormonal contraceptives must
be prescribed and dispensed under the supervision of a health care provider,
because professional medical judgment is warranted for selection of
formulation, evaluation of drug-interactions, and assessment of patients’
medical and contraceptive history.

54. See Martin & Barbieri, supra note 45.
55. Id.
56. See id.; Dawn Stacey, 10 Medications That Decrease Your Hormonal Contraception
Effectiveness, VERYWELL HEALTH (Mar. 27, 2019), https://www.verywellhealth.com/medicationsthat-can-cause-interactions-with-the-pill-906876.
57. US Selected Practice Recommendations for Contraceptive Use, 2016, CTRS. FOR DISEASE
CONTROL & PREVENTION (Feb. 1, 2017), https://www.cdc.gov/reproductivehealth/contraception/
mmwr/spr/combined.html.
58. Id.
59. Id.; Migraine Headaches, JOHN HOPKINS MED., https://www.hopkinsmedicine.org/health
library/conditions/nervous_system_disorders/migraine_headaches_85,P00814 (last visited Apr. 2,
2019) (describing signs and symptoms of migraines).
60. US Selected Practice Recommendations for Contraceptive Use, 2016, supra note 57.
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Plan B: From Prescription-Only to Non-Prescription

The FDA has authority to assign “non-prescription” status to a drug. As per
21 U.S.C. § 353(b)(3), the FDA can “remove drugs subject to [prescription-only
requirements] . . . when such requirements are not necessary for the protection
of the public health.” 61 The FDA can switch only where the evidence
demonstrates that the drug’s dispensing requirements are no longer “necessary
for the protection to public health” due to its toxicity or its potential side effects
and that the drug is safe and effective for the proposed self-use, without
supervision of a practitioner. 62 Thus, the FDA can switch a drug from
prescription-only to non-prescription status.
Levonorgestrol, currently marketed as Plan B, is an emergency
contraceptive that was recently switched to non-prescription status by the FDA,
increasing women’s access to it. Emergency contraceptives are hormonal
contraceptives that are used to prevent pregnancy when taken within seventytwo hours after unprotected sex. 63 Many professional medical groups, including
the American Medical Association and the Association of Reproductive Health
Professionals, advocated for making levonorgestrel available as a nonprescription drug. 64 Levonorgestrel was well tolerated and safe based on the
extensive safety data from clinical studies where more than 15,000 women took
various doses of it for emergency contraception. 65 Moreover, the data collected
from comprehensive research in literature and unpublished study reports did not
uncover any major side effects. 66 There were no serious adverse events reported
during the ongoing studies or from introductory trials that were related to the use
of levonorgestrel. 67 Also, no major side effects, such as thromboembolic events
or ectopic pregnancies, were reported with these studies, a concern that exists
with all prescription-only hormonal contraceptives. 68 Therefore, based on
scientific data from clinical trials, there was no medical reason to restrict
levonorgestrel to prescription-only status.

61. 21 U.S.C. § 353(b)(3) (2012).
62. See id.; 21 C.F.R. 310.200(b) (2016).
63. Heather M. Field, Comment, Increasing Access to Emergency Contraceptive Pills through
State Law Enabled Dependent Pharmacist Prescribers, 11 UCLA WOMEN’S L. J. 141, 147 (2000).
64. Louis Cantilena, Coalition Letter to the USFDA Urging the Nonprescription Drugs
Advisory Committee to Change the Status of Emergency Contraceptive from Rx to Over-theCounter, ACLU, https://www.aclu.org/letter/coalition-letter-usfda-urging-nonprescription-drugsadvisory-committee-change-status (last visited Apr. 5, 2019).
65. See CTR. FOR DRUG EVALUATION & RESEARCH, APPROVAL PACKAGE FOR:
APPLICATION NUMBER: NDA 021998/S-002 63–75 (2013), https://www.accessdata.fda.gov/drugs
atfda_docs/nda/2013/021998Orig1s002.pdf.
66. Id. at 1.
67. Id. at 40 (noting “miscarraige is a common outcome of pregnancy and the relationship of
this event to [levonorgestrel] could not be definitely established.”).
68. Id. at 59.
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Levonorgestrol’s switch to non-prescription status was achieved in a quite
controversial manner, signifying the FDA’s difficulty in regulating hormonal
contraceptives and the public’s interest in availability of these drugs. 69 In
February 2011, Teva Pharmaceuticals submitted an application to make
levonorgestrel available as non-prescription. 70 In December 2011, the FDA was
set to approve non-prescription status with no age restriction based on the studies
submitted by Teva. 71 However, this action was overruled by the Secretary of
HHS. 72 Teva then filed an amended application with additional substantial
data. 73 The Center for Reproductive Rights filed a lawsuit against the Secretary
in the federal district court of New York for overruling on the FDA’s decision. 74
In April 2013, the court ordered the FDA to allow over-the-counter sales of
levonorgestrel with no age restriction. 75 The court stated that “the secretary’s
action was politically motivated, scientifically unjustified, and contrary to
agency precedent.” 76 In June 2013, levonorgestrel became available as a nonprescription drug without age restriction and is marketed as Plan B throughout
the country. 77 In most pharmacies, it is located on the shelf in the family
planning aisle; some pharmacies may choose to keep it in a locked cabinet. 78
Hence, the FDA has authority to switch a drug to non-prescription status.
Plan B is an example of a hormonal contraceptive that was recently switched to
non-prescription status by the FDA, making it available as an over-the-counter
medication for women.
IV. OREGON MODEL’S IMPLICATIONS
This Part will analyze the scope of Oregon’s new law and describe whether
Oregon, and states in general, is in a better position to regulate practice of health
care professionals compared to the FDA. This Part further will examine whether
allowing pharmacists to prescribe hormonal contraceptives can actually increase
access to such drugs. Moreover, this Part will investigate whether women feel
safe in receiving hormonal contraceptive prescriptions from pharmacists and
whether pharmacists can prescribe them safely. Finally, this Part will assess

69. See Alexandra Sifferlin, Timeline: The Battle for Plan B, TIME (June 11, 2013),
http://healthland.time.com/2013/06/11/timeline-the-battle-for-plan-b/.
70. See CTR. FOR DRUG EVALUATION & RESEARCH, supra note 65; Sifferlin, supra note 69.
71. Sifferlin, supra note 69.
72. Id.
73. See id.
74. See Tummino v. Hamburg, 936 F. Supp. 2d 162, 164, 194 (E.D.N.Y. 2013).
75. Id. at 197.
76. See id. at 192.
77. See Sifferlin, supra note 69.
78. Diana Yap, Plan B One-Step Now on Store Shelves, AM. PHARMACISTS ASS’N (Aug. 20,
2013), http://pharmacist.com/plan-b-one-step-now-store-shelves.
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whether Oregon’s new law increases costs for patients and for the health care
system.
A.

Oregon’s Power to Regulate the Practice of Health Care Professionals

Oregon enacted a statute, section 689.683(1) of the Oregon Revised Statute,
which went into effect on January 1, 2016 and expanded the scope of the practice
of pharmacists. The statute provides that pharmacists can prescribe and dispense
self-administered hormonal contraceptives. 79 The statute authorizes pharmacists
to prescribe two formulations of hormonal contraceptives: oral pills and patches.
A pharmacist cannot prescribe other formulations such as injections, IUDs, and
implants, as discussed in Part II, Section A. The statute further states that “a
pharmacist may prescribe . . . hormonal contraceptive patches and selfadministered oral hormonal contraceptives to a person who is: (a) [a]t least 18
years of age . . .; or (b) [u]nder 18 years of age, only if the person has evidence
of a [such] previous prescription from a primary care practitioner . . . .” 80
Essentially, the statute poses age requirements where patients younger than
eighteen years of age cannot receive a prescription from a pharmacist without a
previous prescription from a primary care provider. “This caveat ensures that
women will still receive the recommended screenings,” like a Pap test for their
first prescription from primary care providers. 81 However, patients who are
younger than eighteen years of age are not completely deprived of receiving
hormonal contraceptives. They still can receive their first prescription from a
primary care provider. Primary care providers also have the authority to
prescribe hormonal contraceptives, and Oregon’s practice of medicine statute
does not pose any age limitations on hormonal contraceptives. 82 Interestingly,
this expanded scope of the practice of pharmacy overlaps with the scope of the
practice of medicine at least on the part of prescribing oral and transdermal
hormonal contraceptives.
Oregon’s new law only regulates the practice of pharmacy, a role for states
that the Supreme Court has acknowledged as constitutional. The Court has
determined that states are granted power to regulate the practice of health care
professionals through the Fourteenth Amendment. 83 The expanded scope of the
practice of pharmacists in Oregon does not contradict the FDA’s approval of
hormonal contraceptives. This lies in contrast to Zogenix, Inc. v. Patrick,
discussed in Part II, Section B, where Massachusetts attempted to prohibit the
79. OR. REV. STAT. ANN. § 689.683(1) (West 2016) (amended 2017).
80. Id.
81. Erin N. Deja & Joseph L. Fink III, Pharmacists Prescribing Birth Control: Improving
Access and Advancing the Profession, PHARMACY TIMES (Nov. 16, 2016), http://www.pharmacy
times.com/publications/issue/2016/november2016/pharmacists-prescribing-birth-control-improv
ing-access-and-advancing-the-profession.
82. See OR. REV. STAT. § 677.089 (2017).
83. Graves v. Minnesota, 272 U.S. 425, 427 (1926).
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use of an FDA-approved drug in the state and made the drug completely
unavailable for its citizens. 84 The court held Massachusetts’s law invalid,
because it was regulating drugs contrary to FDA’s decision, that is, what
physicians can or cannot prescribe. 85 Here, Oregon is not prohibiting or
disapproving the use of FDA-approved hormonal contraceptives within its
borders. It is only regulating who can prescribe them, particularly providing
pharmacists with such authority, and not what practitioners can or cannot
prescribe. Hence, this regulation does not regulate drugs and clearly falls within
regulating the practice of health care professionals. Also, the FDA’s
determination that hormonal contraceptives be prescribed under supervision of
a practitioner is not contradicted by Oregon’s new law, because hormonal
contraceptives are still required to be prescribed under the supervision of a
pharmacist. 86
In fact, there are some examples where states have expanded the scope of
the practice of pharmacists. In Florida, a pharmacist can prescribe otic
analgesics, anti-nausea preparations, and topical antibacterials from a formulary
defined in the statute. 87 In California, a pharmacist can prescribe emergency
contraception drugs, nicotine replacement products, and “medications not
requiring a diagnosis . . . for individuals traveling outside of the United
States.” 88 Thus, some states have expanded the scope of the practice of
pharmacists where they can prescribe medications from approved formularies.
Oregon, and states in general, is in better position than the FDA to expand
and regulate the practice of health care professionals for three major reasons.
First, Oregon will be able to serve its citizens more effectively than the FDA,
because Oregon has the expertise to understand local needs of its citizens and
can quickly respond to challenges with new laws if need be. Even though it is
suggested that such state experimentation may threaten public health, 89 the
needs of the citizens might worsen with the FDA regulation of pharmacists,
because it would be too expansive in scope, missing specific details required to
address local needs, and be oppressive and binding on other states.

84. Zogenix, Inc. v. Patrick, No. 14-11689-RWZ, 2014 WL 1454696, at *1 (D. Mass. Apr.
15, 2014).
85. See id. at *2–3 (emphasis added).
86. Pharmacists are recognized as health care providers in Oregon. See OR. REV. STAT.
§ 689.295 (2017); Loren Bonner, Pharmacist Provider Status Now Law in Oregon, PHARMACY
TODAY (July 28, 2015), https://www.pharmacist.com/article/pharmacist-provider-status-now-laworegon.
87. FLA. STAT. § 465.186 (2018); FLA. ADMIN. CODE ANN. r. 64B16-27.220 (2007).
88. CAL. BUS. & PROF. CODE § 4052(a)(10) (2018).
89. See Robert L. Glicksman & Richard E. Levy, A Collective Action Perspective on Ceiling
Preemption by Federal Environmental Regulation: The Case of Global Climate Change, 102 NW.
U. L. REV. 579, 594–600 (2008).
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Second, allowing the FDA to govern the practice of pharmacists may restrict
pharmacists’ flexibility in successfully carrying out their duties and obligations
to their patients. The FDA regulation may force pharmacists to provide care not
based on their judgment of an individual patient’s best interests, but instead
based on overall public health objectives. 90 For instance, the federal Drug
Enforcement Agency’s current restrictions on the use of certain opioid drugs,
aimed at reducing opioid drug abuse nationally, make it challenging for
practitioners to treat patients that have genuine medical needs. 91
Third, because the FDA lacks state-specific focus and maintains general
nationwide presence, the FDA’s enforcement of pharmacists’ practice in Oregon
specifically would become challenging. There is evidence that federally
regulating the practice of health care professionals has been unsuccessful. For
example, an estimated thirty percent of human growth hormone drugs prescribed
by physicians is for off-label uses that are not approved by the FDA. 92 On the
other hand, there is an argument that federal supervision is required in many
cases. For instance, in April 2011, Colorado identified adulterated drugs
compounded by a Massachusetts’s pharmacy and blocked their sales in the
state. 93 Even though Colorado had promptly notified Massachusetts,
Massachusetts was unable to stop the adulterated drugs from reaching and
harming patients in other states. 94 In this case, it is likely that the FDA’s
supervision over compounding practices could have prevented the production of
adulterated drugs.
It is true that for certain problems uniform policy and federal supervision is
necessary; 95 however, in cases where patient-specific and local needs are
considered, like women’s access to certain federally-approved drugs, states
should have the authority to regulate. Federal regulation is generally warranted
when health care practice within states contributes to a national public health
concern that the states are unable to address. 96 When the states have already
established coherent measures to regulate the practice of health care
professionals effectively, then there should be no need for federal agencies to
intervene. 97
90. See Patricia J. Zettler, Toward Coherent Federal Oversight of Medicine, 52 SAN DIEGO
L. REV. 427, 487 (2015).
91. See Veterans Complain New Painkiller Rules Increase Their Suffering, SFGATE (Feb. 18,
2015), https://www.sfgate.com/nation/article/Veterans-complain-new-painkiller-rules-increase-60
88081.php.
92. Mary Lee Vance, Can Growth Hormone Prevent Aging?, 348 NEW ENG. J. MED. 779, 780
(2003).
93. Kevin Outterson, The Drug Quality and Security Act—Mind the Gaps, 370 NEW ENG. J.
MED. 97, 97 (2014).
94. Id.
95. Zettler, supra note 90, at 481.
96. Id. at 482.
97. Id.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

382

B.

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

[Vol. 12:367

Impact on Access to Hormonal Contraceptives

In a news release on May 27, 2015, the Chair of Oregon Legislature Rules
Committee, Val Hoyle, stated that “[i]ncreasing access to birth control is one of
the most important things we can do to improve the lives and health of women
from all walks of life.” 98 She further stated that “[w]e all share the goal of
reducing the number of unwanted pregnancies, and one of the most effective
ways we can do that is to increase access and availability of contraceptives for
women across the state from every background.” 99 The legislative intent behind
Oregon’s new law is to increase access for women to hormonal contraceptives
in the state in order to reduce unintended pregnancies. Oregon’s new law
attempts to achieve this goal by making it easier for women to obtain hormonal
contraceptive prescriptions directly from pharmacy stores as compared to
scheduling an appointment and waiting to receive a prescription from a primary
care provider.
A qualitative study was conducted with twenty reproductive health
practitioners, including physicians and advanced practice clinicians, in
California from 2008 to 2009. 100 The study concluded that most providers
considered prescription-only access to hormonal contraceptives to be too
restrictive. 101 The providers suggested that the rates of unintended pregnancies
can be reduced by increasing access to hormonal contraceptives through
pharmacists via education and training. 102
With Oregon’s new law, based on the increase in the number of prescribers,
it is clear that more health care professionals will now be able to prescribe
hormonal contraceptives, because along with primary care providers,
pharmacists can also now prescribe them. However, research data needs to be
analyzed to determine whether women are willing to receive prescriptions from
pharmacists and whether allowing pharmacists to prescribe can actually increase
access to hormonal contraceptives.
A survey was conducted across the country to better understand women’s
experiences with hormonal contraceptives and their interest in gaining direct
access to them. In this study, a telephone survey was conducted in the U.S. on

98. Scott Moore, House Rules Committee Advances Bill Allowing Pharmacists to Prescribe
Birth Control, LUND REP. (May 27, 2015), https://www.thelundreport.org/content/house-rulescommittee-advances-bill-allowing-pharmacists-prescribe-birth-control.
99. Oregon House Votes to Expand Access to Birth Control, OR. LEGISLATURE (June 2, 2015),
https://www.oregonlegislature.gov/housedemocrats/Documents/Pharmacy%20Birth%20Control
%20Press%20Release.pdf.
100. Sally Rafie et al., Direct Pharmacy Access to Hormonal Contraception: California
Physician and Advanced Practice Clinician Views, 86 CONTRACEPTION 687, 688–89 (2012).
101. Id. at 689.
102. Id. at 692.
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811 women aged 18–44 years who were at risk for unintended pregnancy. 103
The survey looked at women’s readiness and comfort with obtaining hormonal
contraceptives from pharmacists without first visiting a clinic or a physician. 104
The results showed that sixty-eight percent of women in the U.S. said they will
use a pharmacy to access hormonal contraceptives. 105 Likely users included
women not using contraception who would begin using hormonal contraceptives
(forty-one percent) if they were available directly in pharmacies, and oral pills,
patch, or ring users (sixty-six percent) were interested in obtaining their method
from pharmacies. 106 Thus, most women are willing to receive hormonal
contraceptive prescriptions from pharmacists.
The result of the above survey was evident in a pilot study conducted in
Washington state. Five organizations––Program for Appropriate Technology in
Health, the Washington State Pharmacists Association, the University of
Washington Department of Pharmacy, the Washington State Board of
Pharmacy, and DDB World-wide Communications Group, Inc.—conducted a
pilot project from February 1998 to June 1999 that allowed pharmacists to
prescribe hormonal contraceptives. 107 The study measured the number of
prescriptions sold and demand for hormonal contraceptives. 108 During this
period, emergency contraceptives held prescription-only status. In this project,
a total of 11,969 prescriptions for emergency contraceptive medications were
prescribed and dispensed by pharmacists at 130 pharmacies. 109 From February
1998 through December 2000, Washington state pharmacists reported having
served 28,649 women and more than 1,000 new emergency contraceptive
prescriptions were initiated by pharmacists per month. 110 Hence, this study
proved that allowing pharmacists to prescribe contraceptives significantly
increased women’s access to hormonal contraceptives.
Thus, research data has shown that women are willing to receive
prescriptions from pharmacists and that allowing pharmacists to prescribe
hormonal contraceptives has actually increased women’s access to the drugs.

103. Sharon Cohen Landau et al., Birth Control Within Reach: A National Survey on Women’s
Attitudes Toward and Interest in Pharmacy Access to Hormonal Contraception, 74
CONTRACEPTION 463, 464 (2006).
104. Id.
105. Id. at 467.
106. Id.
107. Jacqueline S. Gardner et al., Increasing Access to Emergency Contraception Through
Community Pharmacies: Lessons from Washington State, 33 FAM. PLAN. PERSP. 172, 172 (2001).
108. Id.
109. Id.
110. Id. at 174 (emphasis added).
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C. Impact on Safety of Prescribed Hormonal Contraceptives
Many people place substantial trust in pharmacists because of their expertise
in counseling on proper drug use and knowledge on drug interactions. 111
Pharmacists are also trained in optimizing drug therapy for patients suffering
from chronic conditions. 112 In fact, the FDA proposed to establish a new
category of drugs that would allow pharmacists to dispense prescription-only
drugs without a prescription after pharmacists’ intervention as a condition for
safe use. 113 The rationale was that since pharmacists counsel patients on proper
use of prescription-only drugs, they should also be allowed to dispense them for
certain chronic medical conditions such as asthma, high blood pressure, and high
cholesterol, as these conditions are highly undertreated. 114
Even though pharmacists’ image and education seem promising, an inquiry
needs to be made whether women feel safe in receiving prescriptions from
pharmacists and whether pharmacists can prescribe hormonal contraceptives
safely. A community-based intervention study was conducted from 2003 to 2005
in Seattle, Washington that assessed whether women consider it safe to receive
hormonal contraceptive prescriptions from pharmacists. 115 In this study, 214
women and 26 community pharmacists participated. 116 The participating women
provided their medical and contraceptive history, and the participating
pharmacists identified women at risk of unintended pregnancies, measured their
weight and blood pressure, and prescribed them hormonal contraceptives. 117 The
results showed that 195 women (ninety-one percent) were prescribed hormonal
contraceptives by pharmacists, and 136 women (seventy percent) reported
continuing use of hormonal contraceptives. 118 Nearly all women expressed
willingness to continue to see pharmacists for prescriptions and felt safe in
receiving prescriptions from pharmacists. 119 The study also concluded that
pharmacists can effectively prescribe hormonal contraceptives to women. 120

111. Robert Glatter, Should Pharmacists Prescribe Prescription Medications?, FORBES (May
11, 2012), https://www.forbes.com/sites/robertglatter/2012/05/11/should-pharmacists-prescribeprescription-medications/#5b191b825fcc.
112. See, e.g., Pharm. D. Curriculum, OR. ST. U. C. OF PHARMACY, http://pharmacy.oregon
state.edu/pharm-d-curriculum (last visited Apr. 5, 2019).
113. AM. PHARMACISTS ASS’N, 2013 HOUSE OF DELEGATES REPORT OF THE POLICY
COMMITTEE: REVISIONS TO THE MEDICATION CLASSIFICATION SYSTEM ENSURING ACCESS TO
PHARMACISTS’ SERVICES MEDICATION TAKE BACK/DISPOSAL PROGRAMS 8 (2013).
114. Glatter, supra note 111.
115. Jacqueline S. Gardner et al., Pharmacist Prescribing of Hormonal Contraceptives: Results
of the Direct Access Study, 48 J. AM. PHARMACISTS ASS’N 212, 212 (2008).
116. Id.
117. Id.
118. Id.
119. Id.
120. Gardner et al., supra note 107, at 174, 175.
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Thus, there is evidence that women feel safe in receiving prescriptions from
pharmacists.
Moreover, a fourteen-month study was conducted in California that
compared prescribing abilities of pharmacists and physicians. 121 The patients
were assigned one of two groups, one treated by pharmacists and the other by
physicians. 122 There was no significant difference between the two patient
populations. 123 The study assessed prescribing abilities in six different
measures: (1) was the chosen drug appropriate for diagnosis; (2) are drug
interactions properly checked; (3) was quantity appropriately prescribed; (4) was
the dose proper; (5) were patient directions clear and safe; and (6) will the
prescription have a positive effect on the patient’s health. 124 Pharmacists and
physicians prescribed from a formulary containing more than 300 drugs like
antihypertensives, antidiabetics, and thyroid medications. 125 The results
revealed that in measure one, pharmacists scored better than the physicians in
choosing drugs most appropriate for the diagnosis, with the difference being
statistically significant (p<0.01, t=-2.61). 126 In measures two, three, four, and
five, although the difference was not statistically significant, pharmacists had
better scores than physicians. 127 In fact, in measure six, which assessed whether
the prescription would have a positive effect on the patient’s health, pharmacists
received better scores than physicians with the difference being statistically
significant (p<0.05, t=-2.51). 128 The study concluded that because of
pharmacists’ expertise in pharmacology and rational drug use, pharmacists can
prescribe at least as well as, and on some measures, more appropriate than
physicians. 129 Thus, there is evidence that pharmacists can prescribe
medications safely.
When it comes to hormonal contraceptives, there is less complication
involved in making prescribing decisions than with other prescription-only
drugs. Other prescription-only drugs, such as antihypertensives, antidiabetics,
thyroid medications, etc., require complex clinical tests like electrolyte levels,
blood sugar levels, blood hormone levels, and complete blood counts before they
are prescribed. 130 In comparison, hormonal contraceptives only require
121. William F. McGhan et al., A Comparison of Pharmacists and Physicians on the Quality
of Prescribing for Ambulatory Hypertensive Patients, 21 MED. CARE 435, 437 (1983).
122. Id. at 439.
123. Id. at 441.
124. Id.
125. Id. at 438–39.
126. McGhan et al., supra note 121, at 442–44.
127. Id.
128. Id.
129. Id.
130. AM. C. OF CARDIOLOGY, 2017 GUIDELINE FOR THE PREVENTION, DETECTION,
EVALUATION, AND MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS 1, 13 (2017); AM.
DIABETES ASS’N, Standards of Medical Care in Diabetes–2017, 40 DIABETES CARE 1, S66–69
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measurement of weight, BMI, and blood pressure before prescribing. 131 Other
prescription-only drugs are required to be dose-adjusted based on fluctuating
blood pressure, electrolyte levels, and hormone levels. 132 In contrast, hormonal
contraceptives do not require daily monitoring of clinical health status and are
not dose-adjusted. 133 Also, hormonal contraceptives do not have more drug
interactions or a more severe side effect profile compared to most other
prescription-only drugs. 134 As shown in the study mentioned previously and also
corroborated by other studies, pharmacists have safely prescribed more-intense
and less-safe prescription-only drugs to patients. 135 Thus, pharmacists are
professionally competent to prescribe hormonal contraceptives safely.
In addition to the expertise pharmacists already possess, Oregon has
established training requirements for pharmacists to ensure safe prescribing of
hormonal contraceptives. Pharmacists throughout the state are required to
complete a certification course before they are allowed to prescribe hormonal
contraceptives. 136 This course is developed under the guidance of the Oregon
Board of Pharmacy and accredited by the Accreditation Council for Pharmacy
Education. 137 The program provides a stronger foundation on formulations and
risks of hormonal contraceptives, educates pharmacists on counseling patients
in missed pill situations, and teaches pharmacists to assess patients’ eligibility
for a prescription. 138 Moreover, a questionnaire and an algorithm, drafted by the
Oregon Board of Pharmacy, can be used by pharmacists to obtain adequate
medical and contraceptive history. The questionnaire asks a patient to state her
name, health care provider, date of birth, date of last health clinic visit, and

(Supp. I 2017); AM. THYROID ASS’N, 2016 American Thyroid Association Guidelines for
Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis, 30 THYROID
1343, 1355–57 (2016).
131. US SELECTED PRACTICE RECOMMENDATIONS FOR CONTRACEPTIVE USE, 2016, supra
note 57.
132. AM. C. OF CARDIOLOGY, supra note 130, at 13; AM. DIABETES ASS’N, supra note 130, at
S66–69; AM. THYROID ASS’N, supra note 130, at 1355–57.
133. US SELECTED PRACTICE RECOMMENDATIONS FOR CONTRACEPTIVE USE, 2016, supra
note 57.
134. Martin & Barbieri, supra note 45, at 6.
135. McGhan et al., supra note 121, at 442–44 (describing other studies that proved that
pharmacists can prescribe prescription-only medications safely).
136. Comprehensive Contraceptive Education for the Oregon Pharmacist, OR. ST. U. C.
PHARMACY, https://pace.oregonstate.edu/catalog/comprehensive-contraceptive-education-oregonpharmacist (last visited Apr. 1, 2019).
137. Id.
138. Id.
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health insurance status. 139 There are also questions related to the patient’s
medical and family history. 140
Following the prescribing and dispensing of the hormonal contraceptive, the
pharmacist must give the patient a “Pharmacist Referral and Visit Summary”
form. 141 When the patient is prescribed a medication, the form will state “Today
you were prescribed the following hormonal contraceptive” and name the
medication. 142 If the patient is not eligible for a prescription, the form will state
that “I am not able to prescribe hormonal contraception to you today,” and list
three possible reasons: (1) the patient has a health condition that requires further
evaluation, (2) the patient takes medications that may interfere with hormonal
contraceptives, or (3) the patient’s blood pressure is greater than 140/90
mmHg. 143 Thus, Oregon has developed effective training and procedural
measures to ensure that hormonal contraceptives are prescribed safely.
The results of clinical studies show that women feel safe in receiving
prescriptions from pharmacists. Pharmacists can prescribe at least as safely, and
in some aspects, more appropriately than physicians. Also, the training and
procedural requirements established by Oregon further strengthen the safety
measures.
D. Impact on Costs for Patients and for the Health Care System
The cost of unintended pregnancies on the health care system is extremely
high. Births from unintended pregnancies resulted in approximately twenty-one
billion dollars in government expenditures in 2010. 144 Women with unintended
pregnancy must either choose to deliver the baby, undergo abortion, or plan for
adoption; each of these choices involves significant cost for a woman and for
the health care system. As a result, it is proposed that increasing access to
contraceptives could reduce the cost for the health care system. Based on recent
estimates, each dollar spent on publicly-funded contraceptive services will likely
save $5.68 for the health care system. 145
139. OR. BD. OF PHARMACY, Hormonal Contraceptive Self-Screening Questionnaire,
http://www.oregon.gov/pharmacy/Imports/ContraceptivePrescribing/ORSelf
OREGON.GOV,
ScreeningRiskAssessmentQuestionnaire12.17.pdf (last visited Apr. 13, 2019).
140. OR. BD. OF PHARMACY, Standard Procedures Algorithm for Prescribing of
Contraceptives, OREGON.GOV, http://www.oregon.gov/pharmacy/Imports/ContraceptivePrescrib
ing/OregonStandardProceduresAlgorithmforRPhPrescribing12.17.pdf (last visited Apr. 13, 2019).
141. Vivian, supra note 6.
142. Id.
143. Id.
144. News Release, Guttmacher Inst., Unintended Pregnancies Cost Federal and State
Governments $21 Billion in 2010 (Feb. 3, 2015), https://www.guttmacher.org/print/news-release/
2015/unintended-pregnancies-cost-federal-and-state-governments-21-billion-2010.
145. JENNIFER J. FROST ET AL., GUTTMACHER INST., CONTRACEPTIVE NEEDS AND SERVICES,
2010 27 (2013), https://www.guttmacher.org/sites/default/files/report_pdf/contraceptive-needs2010.pdf.
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A sixteen-month pilot project was conducted in Washington, D.C., that
assessed the cost for patients and for the health care system from increased
availability of hormonal contraceptives. In this study, pharmacists prescribed
hormonal contraceptives to patients. 146 The cost per visit averaged between
thirty and forty dollars, which included contraceptive pills, a medication to
prevent nausea and vomiting, and the pharmacist’s time in assessing, counseling,
and documenting interventions. 147 With this study, however, there was no thirdparty payment service for contraceptive prescriptions. 148 Despite no third-party
financial support, thousands of women paid out-of-pocket to use pharmacists’
services. 149 This study concluded that provision of hormonal contraceptive
prescriptions by pharmacists was a cost-saving measure under all assumptions
for prospective public and private payers. 150 This study also reported a decline
in unintended pregnancies in Washington, D.C., as abortions rates had reached
the lowest level in two decades, dropping by five percent, and teenage pregnancy
rates were seven percent lower during the study period. 151 Thus, there is
evidence that increasing access to hormonal contraceptives through pharmacists
reduces unintended pregnancies.
Oregon has taken several measures to ensure that excessive financial burden
on patients is avoided. In Oregon, under the new law, hormonal contraceptive
prescriptions from pharmacists are covered by insurance. 152 Under a separate
law, health plans must pay for up to a three-month supply for the first fill and up
to a twelve-month supply for these prescriptions. 153 Moreover, Oregon has also
passed the “pharmacist provider status” law that recognizes pharmacists as
providers for billing purposes. 154 Most Oregon pharmacists have a National
Provider Identification number to bill for immunizations, and the state has also
established a billing pathway for them to get reimbursed for hormonal
contraceptives. 155 They will be reimbursed at the same rate as other
prescribers. 156 Patients with valid insurance will pay nothing or at least a reduced
cost for their prescriptions, depending on their insurance coverage. If a patient is
determined not eligible for hormonal contraceptive prescription and is referred
to a physician, then the pharmacist will not charge insurance for the services. 157
146.
147.
148.
149.
150.
151.
152.
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Thus, patients likely will not have excessive financial burden when obtaining
hormonal contraceptives prescribed by pharmacists.
Therefore, there is evidence that increasing access to hormonal
contraceptives reduces unintended pregnancies, and thereby, costs for the health
care system. In Oregon, since hormonal contraceptive prescriptions from
pharmacists will be covered by insurance, patients with valid insurance will pay
nothing or a reduced cost for their prescriptions.
V. CONCLUSION
There is a distinction between the power of the FDA and states regarding
protection of the public. The FDA has authority to regulate medical products,
which allows it to be actively involved at every step of their approval process.
The states have the authority to regulate the practice of health care professionals,
because this power has been granted to them by the Fourteenth Amendment and
has been acknowledged by the Supreme Court of the United States.
Oregon, and states in general, is in a better position than the FDA to regulate
the practice of health care professionals. First, Oregon will be able to respond to
local access needs of its citizens more quickly than the FDA. Second, Oregon
can enact laws that will allow health care professionals to address clinical needs
of individual patients better than the FDA. Third, Oregon can enforce
regulations and supervise the practice of health care professionals more closely
and effectively than the FDA.
This Article has shown that Oregon’s model offers strong solutions that
likely resolves all concerns of the legal and medical communities. Oregon’s law
will increase access to hormonal contraceptives. The clinical studies have shown
that allowing pharmacists to prescribe hormonal contraceptives actually
increases access to them, because women are willing and feel safe to receive
hormonal contraceptive prescriptions from pharmacists. Oregon’s law will not
jeopardize safety of women’s health; rather it will improve their health. The
clinical studies have proved that pharmacists can prescribe medications safely,
in fact, better than physicians can. Oregon’s law will not increase costs for
patients and for the health care system. The studies have shown that increasing
access to hormonal contraceptives reduces unintended pregnancy and abortion
rates, which decreases overall health care costs. Also, with Oregon’s model, the
cost for patients will not increase, because prescriptions from pharmacists will
be covered by insurance and patients will pay nothing or receive a reduced cost
for their prescriptions.
Oregon’s model will serve as a prime example of a state’s effort in
regulating the practice of health care professionals. Oregon’s efforts likely will
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inspire other states to expand the scope of the practice of pharmacists and
empower pharmacists to enhance health care in the country.
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